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The proteasome is a therapeutic target in cancer, but resistance to proteasome inhib-
itors often develops owing to the induction of compensatory pathways. Through a
genome-wide siRNA screen combined with RNA sequencing analysis, we identified
hexokinase and downstream O-GlcNAcylation as cell survival factors under protea-
some impairment. The inhibition of O-GlcNAcylation synergistically induced massive
cell death in combination with proteasome inhibition. We further demonstrated that
O-GlcNAcylationwas indispensable formaintainingproteasomeactivitybyenhancing
biogenesis as well as proteasome degradation in a manner independent of Nrf1, a
well-known compensatory transcription factor that upregulates proteasome gene
expression. Our results identify a pathway thatmaintains proteasome function under
proteasome impairment, providing potential targets for cancer therapy.
INTRODUCTION
The proteasome is responsible for the degradation of regulatory and misfolded proteins that are ubiquiti-
nated within eukaryotic cells, and it plays pivotal roles in various cellular events such as the cell cycle, DNA
repair, signal transduction, and protein quality control (Murata et al., 2009). Cancer cells often have high
proteasome activity to improve their growth and survival (Arlt et al., 2009; Chen and Madura, 2005; Kuma-
tori et al., 1990; Schwartz and Ciechanover, 2009). Inhibition of the proteasome causes proteotoxic stress
that leads to cell-cycle arrest and apoptosis in cancer cells, and it is now widely accepted that the protea-
some is an attractive therapeutic target in cancer (Manasanch and Orlowski, 2017).
The US Food and Drug Administration-approved proteasome inhibitors bortezomib, carfilzomib, and ixa-
zomib are used for the treatment of multiple myeloma and have led to significant improvements in the clin-
ical outcomes of patients with this condition (Kubiczkova et al., 2014). Unfortunately, most patients ulti-
mately relapse because surviving cancer cells acquire drug resistance (Wallington-Beddoe et al., 2018).
In patients with multiple myeloma, several drugs are available for overcoming drug resistance, including
immunomodulatory agents, histone deacetylase inhibitors, and monoclonal antibodies (Kubiczkova
et al., 2014; Kurtin and Bilotti, 2013). Although these drugs improve clinical outcomes, they do not
completely overcome bortezomib resistance, probably because they do not directly target the pathways
that confer resistance to proteasome inhibitors (Manasanch and Orlowski, 2017).
Recent studies have shown that multiple myeloma cells acquire resistance to proteasome inhibitors in
several ways, such as mutation of the b5 subunit, a direct target of bortezomib (Lü et al., 2008; Oerlemans
et al., 2008); induction of multidrug transporters (Besse et al., 2018); suppression of endoplasmic reticulum
(ER) stress sensors (Leung-Hagesteijn et al., 2013); activation of the bounce-back response mediated by
Nrf1, which induces proteasome subunits (Radhakrishnan et al., 2010; Steffen et al., 2010); upregulation
of antioxidant responses (Riz et al., 2016; Weniger et al., 2011); and alteration of metabolic pathways,
including glycolysis (Maiso et al., 2015; Zaal et al., 2017). However, the mechanisms by which cancer cells
escape the cytotoxic effects of proteasome inhibitors remain controversial because proteasome inhibi-
tor-resistant cancer cells accompany various genomic mutations and alterations.
In this study, we performed a nonbiased genome-wide analysis and identified hexokinase 1 (HK1), and sub-
sequently O-GlcNAc transferase (OGT), as cell death suppressors under proteasome impairment. WeiScience 23, 101299, July 24, 2020 ª 2020 The Author(s).





Articledemonstrated that combined inhibition of both O-GlcNAcylation and the proteasome resulted in synergis-
tic cell death and suppression of tumor growth with deterioration of proteasome activity, suggesting that
enhanced protein O-GlcNAcylation plays a cytoprotective role under proteasome impairment. We further
showed that O-GlcNAcylation promotes turnover of the proteasome by enhancing both its degradation
and biogenesis and thus recovers proteasome activity under proteasome impairment, demonstrating a
new mechanism by which cells maintain proteasome activity.
RESULTS
Identification of Hexokinase 1 as a Cell Death Suppressor under Proteasome Impairment
To understand the compensatory pathways that maintain cell survival under proteasome impairment, we
first determined the bortezomib concentration that inhibits proteasome activity but does not induce
massive cell death. We employed p53-intact U2OS cells to comprehensively understand the cellular re-
sponses to proteasome dysfunction. We treated U2OS cells with various concentrations of bortezomib
and found that 10 nM bortezomib caused only modest cell death (Figure 1A). Compared with 50 nM bor-
tezomib, the concentration that kills most cells, 10 nM bortezomib decreased the peptidase activity of the
proteasome by 25% (Figure 1B) and resulted in modest accumulation of ubiquitinated proteins (Figure 1C).
We presumed that cells barely survive exposure to 10 nM bortezomib and thus expected that inhibiting
compensatory pathways that maintain survival under proteasome impairment would induce cell death. Up-
regulation of de novo proteasome synthesis is a well-known compensatory mechanism for proteasome
impairment. Nrf1 is a transcription factor that is activated to induce the expression of proteasome subunit
genes upon proteasome inhibition (Radhakrishnan et al., 2010; Steffen et al., 2010), and Ump1 is a critical
molecule for proteasome assembly (Murata et al., 2009). Indeed, knockdown of Nrf1 and Ump1 in the pres-
ence of 10 nM bortezomib markedly induced cell death (Figures 1D and S1A).
Thus, we comprehensively screened for genes involved in the compensatory response to proteasome
impairment under 10 nM bortezomib. Of the cell lines tested in a preliminary investigation, including
293T, HeLa, and U2OS cells, we obtainedmost robust and reproducible results by using U2OS cells. There-
fore, we performed a genome-wide siRNA screen in U2OS cells in the presence of 10 nM bortezomib by
monitoring cell death. A total of 1,146 genes with a B score >3 in the primary screen, in which each well
contained amixture of four siRNAs targeting one gene, were further tested using independent siRNAs (Fig-
ures 1E and 1F). We obtained 28 genes with positive results for at least three of the four siRNAs (Figure 1F
and Table S1).
To further narrow the candidate gene list, we performed RNA sequencing (RNA-seq) analysis based on the
assumption that compensatory pathways might be upregulated by proteasome inhibition. We identified
2,322 genes for which the mRNA levels increased by more than 1.8-fold in the presence of 10 nM bortezo-
mib; five of these genes overlapped with the candidates obtained from the siRNA screen (Figures 1G and
1H). This gene list included reasonable factors such as an antiapoptotic factor (BCL2L1) and a stress-induc-
ible ubiquitin gene (UBC), both of which has been known to be involved in resistance to proteotoxic stress,
validating our screening approach (Bianchi et al., 2018; Hagenbuchner et al., 2010) (Figure 1I). In addition, a
glucose phosphorylating enzyme (HK1), a ubiquitin ligase (RNF181), and a putative transcription factor
(ZNF770) of unknown function were identified (Figure 1I). From this list of genes, we chose to focus on
HK1. Mammals have four hexokinase isoforms, of which HK1 is dominantly expressed in U2OS cells (Fig-
ure S1B). HK1 catalyzes the initial step in glucose utilization and is a rate-limiting enzyme in glycolysis,
but the role of glucose metabolism in proteasome dysfunction remains incompletely understood.
Combined Inhibition of the Proteasome and Hexokinase Promotes Cell Death
To confirm that attenuation of HK1 activity promotes cell death in the presence of bortezomib in other cell
types, we treated B16 cells with 2-deoxy-D-glucose (2-DG), a hexokinase inhibitor, in combination with bor-
tezomib. Separate treatment with either 2-DG or bortezomib weakly induced cell death, whereas the simul-
taneous presence of the two reagents markedly enhanced cell death (Figure 2A). We further confirmed the
synergistic cytotoxicity of bortezomib and 2-DG as calculated by the Bliss independencemodel (Figure 2B).
No synergistic effect of 2-DG and bortezomib was observed in HK1-knockdown cells, consistent with the
notion that 2-DG shows an effect primarily through HK1 inhibition, at least in our experimental conditions
(Figure S2), although we cannot exclude the possibility that 2-DG interferes with biological processes other








Figure 1. Genome-wide siRNA Screen for Cell Death Suppressors under Proteasome Inhibition
(A) Viability assay of U2OS cells treated with bortezomib (BTZ) (0–100 nM) for 48 h.
(B) Proteasome peptidase activity of lysates from U2OS cells treated with 10 nM BTZ for 48 h.
(C) Immunoblot analysis of lysates from U2OS cells with antibodies against the indicated proteins. U2OS cells were treated with BTZ (0–50 nM) for 16 h before
harvest.
(D) Viability assay of U2OS cells transfected with Nrf1 and Ump1 siRNAs or control siRNA and then treated with 10 nM BTZ for 48 h.
(E) B score of all samples in the first genome-wide siRNA screen. The results are ordered from lowest to highest. The dashed red line shows the cutoff value of
positive hits in the first screen.
(F) The workflow of siRNA screens. In the first screen, U2OS cells were treated with a pooled siRNA library containing four siRNA constructs per gene. In the
second screen, U2OS cells were treated with four individual siRNAs.
(G) Enrichment analysis of 2,322 genes upregulated by BTZ treatment for 60 h was performed using Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways. The gene expression values were log2 transformed, and GO analysis was performed. Representative data are shown.
(H) Venn diagram showing positive hits from the siRNA screens (red) and genes that were upregulated by BTZ treatment (blue). Five genes were common to
the results of both screens (white).
(I) The final list of five hits and the scores of each assay in the two screens. The percentage of dead cells was assessed by FACS after staining with Hoechst
33,342 and propidium iodide (PI) in (A) and (D). Data in (A), (B), and (D) are the meanG SEM (n = 3). Data in (A) and (B) were analyzed by two-tailed Student’s t
test (*p < 0.05, ***p < 0.001). Data in (D) were analyzed by two-way ANOVA followed by Tukey’s test (***p < 0.001). See also Figure S1 and Table S1.
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Figure 2. Combined Inhibition of the Proteasome and Hexokinase Promotes Cancer Cell Death
(A) Viability assay of B16 cells treated with 10 nM BTZ alone or in combination with 3 mM 2-DG for 48 h. Data are presented
as the mean G SEM (n = 3).
(B) Viability assay of B16 cells treated with various concentrations of BTZ and 2-DG for 48 h. Data are presented as the
mean (n = 3).
(C) Representative tumor allografts are shown.
(D) Mouse allograft model to confirm the effect of combined treatment with BTZ and 2-DG. B16 cells were subcutaneously
transplanted into C57BL/6N mice. Mice were intraperitoneally injected with control (PBS), BTZ (0.5 mg kg1), 2-DG
(1,500 mg kg1), or BTZ (0.5 mg kg1) in combination with 2-DG (1,500 mg kg1) three times per week. Tumor size was
measured using a digital caliper. Data are presented as the mean G SEM (n = 5 mice per group). The percentage of dead
cells was assessed by FACS after staining with Hoechst 33,342 and PI in (A) and (B). Data in (A) and (D) were analyzed by




ArticleThis synergistic effect was further confirmed in an in vivomodel. Treatment of B16 melanoma-bearing mice
with an intraperitoneal injection of bortezomib (0.5 mg kg1) and 2-DG (1,500 mg kg1) showed synergistic
antitumor activity (Figures 2C and 2D). These results suggest that a pathway involving HK1 plays a crucial
role in preventing cell death under proteasome impairment.
Increase in Protein O-GlcNAcylation under Proteasome Inhibition
HK1 is a key enzyme in downstream metabolic pathways, including glycolysis, the pentose phosphate
pathway, and protein glycosylation. To determine which downstream pathway is responsible for the
protective effect under proteasome impairment, we evaluated the result of knocking down or inhibiting
downstream enzymes and measured their mRNA expression and also assessed the stress response
induced by bortezomib.
Although knockdown of HK1 induced cell death in combination with bortezomib, knockdown of glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) and enolase 1 (ENO1) did not show obvious synergistic
cytotoxicity (Figures S3A and S3B). In addition, synergistic treatment with bortezomib and either the pyru-
vate dehydrogenase kinase (PDK) inhibitor sodium dichloroacetate (DCA) or the lactate dehydrogenase
(LDH) inhibitor oxamate had modest effects on cell death compared with those of treatment with bortezo-
mib and 2-DG (Figures S3C and S3D), indicating that glycolysis is not important for suppressing cell death







Figure 3. Increased Protein O-GlcNAcylation Is Required for Cell Survival under Proteasome Inhibition Both In Vitro and In Vivo
(A) Expression heatmap for genes associated with glucose transport, HK, glycolysis, the N-linked and O-linked glycosylation pathways, and O-
GlcNAcylation. Expression data were derived from RNA-seq data.
(B) Immunoblot analysis of lysates from B16 cells with antibodies against the indicated proteins. B16 cells were treated with 10 nM BTZ and 50mMGlcNAc for
48 h and with 1 mM 2-DG for 24 h before harvest. Relative band intensity values for O-GlcNAcylated proteins or OGT were normalized to those for b-actin.
(C) Viability assay of B16 cells treated with 10 nM BTZ and 1 mM 2-DG with or without 20 mM GlcNAc for 48 h.
(D and E) Viability assay of U2OS cells transfected with OGT siRNAs (#01 and #02) or control siRNA in the presence of 15 nM (D) or various concentrations of
BTZ (E) for 48 h. (F) Viability assay of B16 cells treated with the indicated combination of 20 mM OSMI-1 and 10 nM BTZ for 48 h.
(G) Viability assay of B16 cells treated with various concentrations of BTZ and OSMI-1 for 48 h. Data are presented as the mean (n = 3).
(H) Viability assay of B16 cells treated with 25 nM BTZ with or without 20 mM Thiamet-G for 48 h.
(I) Mouse allograft model to confirm the effect of combined treatment with BTZ and OSMI-1. B16 cells were subcutaneously transplanted into C57BL/6N
mice. Mice were intravenously injected with control (PBS), BTZ (0.5 mg kg1), OSMI-1 (0.56 mg kg1), or BTZ (0.5 mg kg1) in combination with OSMI-1
(0.56 mg kg1) three times per week. Representative tumor allografts are shown.
(J) Tumor size was measured using a digital caliper. Data are presented as the mean G SEM (n = 5 mice per group).
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(K) Tumor weight. Data are presented as the mean G SEM (n = 5 mice per group). The percentage of dead cells was assessed by FACS after staining with
Hoechst 33,342 and PI in (C–H).
Data in (B)–(F) and (H) are presented as the meanG SEM (n = 3). Data in (C) and (H) were analyzed by two-tailed Student’s t test (***p < 0.001). Data in (B) and
(D) were analyzed by Tukey’s test (*p < 0.05, ***p < 0.001). Data in (F), (J), and (K) were analyzed by two-way ANOVA followed by Tukey’s test (*p < 0.05, **p <




Articlewith bortezomib and 2-DG, demonstrating that glycolysis was not strongly inhibited in our experimental
conditions (Figure S3E).
The pentose phosphate pathway was also dispensable for cell survival under proteasome inhibition, as
knockdown of glucose-6-phosphate dehydrogenase (G6PD) did not show synergistic cytotoxicity with
bortezomib (Figure S3B).
When we organized the RNA-seq data according to the potentially involved pathways, we found that many
of the genes involved in O-GlcNAcylation, including OGT, were coordinately upregulated in response to
proteasome inhibition, whereas genes involved in glycolysis and glycosylation in the ER and Golgi were not
(Figure 3A). We confirmed the induction of HK1 or OGT mRNA expression under bortezomib treatment in
B16, HEK293T, and RPMI8226 cells (Figure S3F). O-GlcNAcylation is one of the most abundant types of
eukaryotic intracellular glycosylation; OGT catalyzes polypeptide glycosylation by adding N-acetylglucos-
amine (GlcNAc) to serine and threonine residues, whereas O-GlcNAcase (OGA) removes O-GlcNAc moi-
eties from polypeptides (Bond and Hanover, 2015). Previous studies reported that O-GlcNAcylation of pro-
teasome subunits inhibited proteasome activity (Keembiyehetty et al., 2011; Zhang et al., 2003). On the
other hand, recent studies showed that enhanced O-GlcNAcylation of Nrf1 promoted the expression of
proteasome subunits (Sekine et al., 2018) and that increased O-GlcNAcylation of FOXA1 was involved in
bortezomib resistance in breast cancer cells (Liu et al., 2019). Thus, the biological significance of O-GlcNA-
cylation under proteasome inhibition remains elusive.
To determine whether protein O-GlcNAcylation increases in response to proteasome inhibition, we quan-
tified intracellular protein O-GlcNAcylation levels. O-GlcNAcylated proteins increased in cells treated with
bortezomib, and this increase was reversed by the addition of 2-DG and by HK1 knockdown (Figures 3B and
S3G). OGT protein levels also increased in response to bortezomib treatment (Figure 3B). The addition of
GlcNAc, which is known to promote O-GlcNAcylation (Zhang et al., 2017), restored intracellular O-GlcNA-
cylation levels (Figures 3B and S3G). These results are consistent with a previous study reporting increased
O-GlcNAcylated proteins in bortezomib-treated cells (Liu et al., 2019).
Increased O-GlcNAcylation Is Required for Cell Survival under Proteasome Inhibition
In the primary siRNA screen, the B-score of OGT (2.04) fulfilled the commonly used criterion (B-score >1.65,
corresponding to p < 0.05). To investigate whether an increase in O-GlcNAcylation catalyzed by OGT is
involved in cell survival under proteasome impairment, we examined cell viability under conditions that
either enhance or inhibit O-GlcNAcylation. The addition of GlcNAc restored cell viability after combined
treatment with bortezomib and 2-DG in B16 and U2OS cells (Figures 3C and S4A). In addition, knockdown
of OGT and inhibition of OGT activity by the specific OGT inhibitor OSMI-1 enhanced cell death in the pres-
ence of bortezomib (Figures 3D–3F), with synergistic cytotoxicity (Figure 3G). OGT knockdown andOSMI-1
also showed a synergistic effect with another proteasome inhibitor, carfilzomib (Figures S4B and S4C).
Conversely, enhancing protein O-GlcNAcylation by treatment with Thiamet-G, an OGA inhibitor, reduced
the cytotoxicity of bortezomib (Figure 3H). Synergistic cytotoxicity was also observed in U2OS and
RPMI8226 multiple myeloma cells (Figure S4D and S4E), suggesting that the cytoprotection mediated
by O-GlcNAcylation under proteasome impairment is a general event.
Since data from genome-wide siRNA screens in the Cancer Dependency Map (depmap.org) indicate that
many cell lines exhibit decreased viability when OGT is knocked down, we examined whether the synergis-
tic effect of OSMI-1 was also observed with other anti-cancer drugs. We tested thapsigargin, nocodazole,
cisplatin, and 5-fluorouracil, but none of the drugs showed synergistic cytotoxicity with OSMI-1, suggesting
that the synergistic effect of OSMI-1 is at least relatively specific to proteasome inhibitors (Figure S5).
Although bortezomib is used as a first-line drug for the treatment of multiple myeloma, recent studies re-




Article(Dispenzieri et al., 2010; Moreau et al., 2011; Ruschak et al., 2011). We therefore examined whether inhibi-
tion of O-GlcNAcylation sensitized bortezomib-resistant cells to bortezomib. We generated bortezomib-
resistant U2OS (U2OS/BTZ) and B16 (B16/BTZ) cells by culturing cells with bortezomib at stepwise
increasing concentrations for 3 months (Figure S6A and S6B). Combined treatment with OSMI-1 and bor-
tezomib demonstrated synergistic cell death in both U2OS/BTZ and B16/BTZ cells (Figure S6C and S6D).
These results indicate that enhanced protein O-GlcNAcylation is an important mechanism even in borte-
zomib-resistant cancer cells.
We next examined the effects of bortezomib and OSMI-1 in combination using a mouse allograft model.
Concomitant administration of bortezomib and OSMI-1 to B16 melanoma-bearing mice markedly
suppressed tumor development compared with either drug alone (Figures 3I–3K), demonstrating that
OGT inhibition enhances the antitumor effect of bortezomib in vivo.
O-GlcNAcylation Is Involved in Maintaining Proteasome Function upon Proteasome
Impairment
We next addressed the mechanism by which O-GlcNAcylation plays a protective role against proteasome
impairment. We found that combined treatment with bortezomib and OSMI-1 markedly enhanced the
accumulation of ubiquitinated proteins (Figure 4A).
To examine whether this accumulation was caused by increased ubiquitination or defects in proteasomal
degradation, we measured the peptidase activity of the proteasome. Compared with single treatments,
the combined treatment with bortezomib and OSMI-1 decreased proteasome activity (Figure 4B). We
further monitored the fluorescence intensity of U2OS cells expressing ZsGreen-mODC, a model proteaso-
mal substrate that is degraded in a ubiquitin-independent manner. Although monotherapy with bortezo-
mib or OSMI-1 did not affect ZsGreen-mODC degradation, combined treatment with bortezomib and
OSMI-1 caused the accumulation of ZsGreen-mODC (Figure 4C). Knockdown of OGT also caused
ZsGreen-mODC accumulation when combined with bortezomib treatment (Figure 4D). Conversely,
enhancement of O-GlcNAcylation by Thiamet-G reduced the accumulation of ZsGreen-mODC caused
by bortezomib treatment (Figure 4E). Taken together, these results suggest that inducible O-GlcNAcyla-
tion plays an important role in maintaining proteasome function upon proteasome impairment.
Nrf1 Is Not Involved in O-GlcNAcylation-Mediated Proteasome Maintenance
It is well known that compromised proteasome activity is restored by the Nrf1-mediated upregulation of
proteasome subunits (Radhakrishnan et al., 2010; Steffen et al., 2010). It has been reported that Nrf1 is sta-
bilized by O-GlcNAcylation (Sekine et al., 2018), raising the possibility that OGT inhibition attenuates Nrf1
function and thus proteasome function. However, neither OGT knockdown nor OSMI-1 treatment damp-
ened the bounce-back increase in proteasome subunits induced by bortezomib (Figure 4F). Furthermore,
OGT knockdown did not affect the bortezomib-induced increase in the mRNA levels of the proteasome
subunit gene PSMB7, an increase that was abolished by Nrf1 knockdown (Figure 4G), indicating that
OGT inhibition does not disrupt the bounce-back response.
We also showed that the synergistic effect of OSMI-1 and bortezomib on cytotoxicity and proteasome
dysfunction persisted in Nrf1-knockout cells (Figures 4H, 4I, and S6E–S6G). These results indicate that
the bounce-back transcriptional upregulation of proteasome subunits is not altered by the inhibition of
O-GlcNAcylation and that O-GlcNAcylation-mediated proteasome maintenance occurs independently
of Nrf1.
O-GlcNAcylation Maintains Proteasome Activity by Enhancing Turnover of the Proteasome
upon Proteasome Impairment
The observation that proteasome activity was decreased while the proteasome amount was unaffected in-
dicates a decrease in specific proteasome activities by the inhibition of O-GlcNAcylation in the presence of
bortezomib (Figures 4A–4F). To investigate the mechanism by which cells maintain proteasome function-
ality, we monitored the half-life of the proteasome by using HeLa cells in which HaloTag was fused at the C
terminus of the endogenous Rpn11 subunit (Tomita et al., 2018). First, we confirmed the synergistic toxicity
of bortezomib with O-GlcNAcylation inhibition in HeLa cells by conducting a series of experiments (Figures
S7A–S7F). After treatment with or without bortezomib, proteasomes were pulse-labeled by tetramethylr-






Figure 4. Enhanced O-GlcNAcylation Compensates for Proteasome Activity upon Proteasome Inhibition in an Nrf1-Independent Manner
(A and B) Immunoblot analysis with antibodies against the indicated proteins (A) and proteasome peptidase activity (B) of lysates from U2OS cells treated
with 10 nM BTZ for 48 h and with 20 mM OSMI-1 for 24 h.
(C and D) Proteasome activity assay with U2OS cells stably expressing ZsGreen-mODC treated with 20 mM OSMI-1 (C) or transfected with OGT siRNAs
(siOGT#01 and siOGT#02) or control siRNA (D) and then treated with 10 nM BTZ for 48 h.
(E) Proteasome activity assay with HEK293T cells stably expressing ZsGreen-mODC treated with 25 nM BTZ with or without 20 mM Thiamet-G.
(F) Immunoblot analysis of lysates from U2OS cells with antibodies against the indicated proteins. U2OS cells were treated with 20 mMOSMI-1 or transfected
with OGT siRNAs (siOGT#01 and siOGT#02) or control siRNA and then treated with 10 nM BTZ for 48 h.
(G) Relative mRNA expression of proteasome gene PSMB7 in U2OS cells transfected with target siRNAs (siNrf1 or siOGT#02) or control siRNA and then
treated with 10 nM BTZ for 48 h. mRNA levels of target genes were normalized to GUSB mRNA levels.
(H) Viability assay of wild-type (WT) and Nrf1-knockout (KO; KO#01 and KO#02) HCT116 cells treated with 10 nM BTZ for 48 h with or without 20 mMOSMI-1
for 24 h.
(I) Proteasome peptidase activity of lysates from WT and Nrf1-KO (KO#01 and KO#02) HCT116 cells treated with 10 nM BTZ for 48 h with or without 20 mM
OSMI-1 for 24 h.
Data in (B)–(E), (G), (H), and (I) are presented as themeanG SEM (n = 3). Data in (B)–(E), (H), and (I) were analyzed by two-way ANOVA followed by Tukey’s test




Article(Figure 5A). In yeast and plants, impaired proteasomes are known to be degraded by a selective form of
autophagy called proteaphagy (Marshall and Vierstra, 2019). Treatment of bafilomycin A1 extended the
proteasome half-life both in the absence and presence of bortezomib, suggesting that the proteasome








Figure 5. O-GlcNAcylation Enhances Turnover of the Proteasome
(A and B) Schematic view of measuring half-life of the proteasome (A).
HeLa Rpn11-Halo knockin cells were treated with 200 nM BTZ or 20 mM OSMI-1 cells. After 4 h, BTZ was washed out and cells were stained with TMR ligand
and subsequently subjected to the blocking ligand. Cells were incubated at 37C for the indicated times (B).
(C and D) Schematic view of measuring the amounts of newly synthesized proteasomes (C). HeLa Rpn11-Halo knockin cells were treated with 200 nM BTZ or
20 mM OSMI-1. After 4 h, BTZ were washed out and cells were treated with the blocking ligand. Cells were incubated at 37C for 6 h and then stained with
TMR ligand (D).
(E and F) Schematic view of measuring proteasome peptidase activity of newly synthesized proteasomes (E). HeLa Rpn11-Halo knockin cells were treated
with 30 nM CFZ or 20 mM OSMI-1. After 4 h, CFZ was washed out and then cells were incubated at 37C for 18 h. Cells were lysed and immunoprecipitated
with HaloLink Resin (F).
(G) Immunoblot analysis of lysates from HeLa Rpn11-Halo knockin cells treated as in (E) with antibodies against the indicated proteins. Relative band
intensity values for a6 and Rpn8 were normalized to those for b-actin.
Data in (B), (D), (F), and (G) are presented as the meanG SEM (n = 3). Data in (B), (D), and (F) were analyzed by Tukey’s test (*p < 0.05, **p < 0.01, ***p < 0.001,
n.s.: not significant). Data in (G) were analyzed by two-tailed Student’s t test (*p < 0.05, **p < 0.01). See also Figures S7–S10.
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ArticleOSMI-1 treatment and knockdown of OGT also extended the proteasome half-life in the absence or
presence of bortezomib, indicating that O-GlcNAcylation plays a role in degradation of the proteasome
(Figures 5B and S7G).
Despite decelerated degradation of the proteasome by OSMI-1, the amounts of proteasome subunits
were not increased under combined treatment with bortezomib and OSMI-1 or under OGT knockdown
(Figure 4F). We then examined whether O-GlcNAcylation was involved in proteasome biogenesis. After
blocking pre-existing proteasomes by succinimidyl ester ligands, we quantified newly synthesized protea-
somes by labeling them with TMR ligands in the presence or absence of bortezomib and OSMI-1
(Figure 5C). OSMI-1 decreased newly synthesized proteasomes, and the effect was more profound in
the presence of bortezomib (Figure 5D), suggesting that O-GlcNAcylation promotes proteasome biogen-
esis, especially under proteasome impairment.
Next, wemeasured the activity of newly synthesized proteasomes. To this end, we first treated cells with the
irreversible proteasome inhibitor carfilzomib to minimize the activity of pre-existing proteasomes. We then
blocked pre-existing proteasomes by succinimidyl ester ligands and immunoprecipitated newly synthe-
sized proteasomes with HaloLink Resin (Figure 5E). We also measured the activity of ‘‘total proteasomes’’
by using cell lysates before immunoprecipitation. The activity of total proteasomes decreased under com-
bined treatment with carfilzomib andOSMI-1 (Figure 5F, left), similar to the results obtained by bortezomib
treatment (Figure 4B). We found that OSMI-1 decreased the activity of newly synthesized proteasomes, and
the effect was more profound in the presence of carfilzomib (Figure 5F, right), further confirming the role of
O-GlcNAcylation in proteasome biogenesis under proteasome impairment (Figure 5D). The immunopre-
cipitated newly synthesized proteasomes were further subjected to immunoblot analyses of proteasome
subunits. This confirmed the decrease in the amount of newly synthesized proteasomes in OSMI-1-treated
cells (Figure 5G), consistent with the results shown in Figures 5D and 5F. An extended half-life of the pro-
teasome and a decrease in newly synthesized proteasomes were also observed in Rpn11-Halo knock-in
U2OS and B16 cells (Figure S8), validating the involvement of O-GlcNAcylation in proteasome turnover.
Taken together, we conclude that O-GlcNAcylation plays a role in proteasome turnover by promoting both
the degradation and biogenesis of proteasomes to maintain proteasome activity and thus cellular homeo-
stasis under proteasome impairment (Figure 6).DISCUSSION
In the present study, we demonstrated that enhanced protein O-GlcNAcylation was involved in maintain-
ing proteasome function under proteasome inhibition. Prior large-scale genome-wide screens identified
genes that are involved in the sensitization or resistance to proteasome inhibitors, but none identified
HK1 or OGT (Acosta-Alvear et al., 2015; Tsvetkov et al., 2015). This is probably due to differences between
our study and these previous ones in terms of experimental conditions such as cell lines and inhibitor con-
centrations. Prior studies reported that various mechanisms are involved in the acquired resistance to pro-
teasome inhibitors, including the Nrf1-mediated expression of proteasome subunits (Radhakrishnan et al.,
2010; Steffen et al., 2010) and the activity of drug transporters (Besse et al., 2018). Although these reports
raise the possibility that enhanced O-GlcNAcylation contributes to the regulation of these compensatory
mechanisms, our data demonstrated that O-GlcNAcylation mediated the maintenance of proteasome ac-
tivity independently of Nrf1 (Figures 4G–4I). Unlike a previous report (Sekine et al., 2018), our study showed
that O-GlcNAcylation was not involved in the Nrf1-mediated compensatory increase in proteasomes. This
discrepancy is probably due to differences in experimental conditions, including cell types and the degree
of proteasome inhibition. However, our finding demonstrated a new compensatory role of O-GlcNAcyla-
tion in proteasome impairment that is independent of Nrf1. We also showed that the activity of ABCB1,
which is known to efflux bortezomib and carfilzomib (Ao et al., 2012; O’Connor et al., 2013; Verbrugge
et al., 2012), was not attenuated under O-GlcNAcylation inhibition (Figure S9).
We demonstrated that enhanced O-GlcNAcylation promoted turnover of the proteasome under proteasome
impairment, although further analyses are required to elucidate the detailed mechanisms underlying enhanced
proteasome degradation and the biogenesis of the proteasome by O-GlcNAcylation. Considering that neither
mRNA levels of proteasome subunits nor the assembly pathway of the proteasome was affected by OGT knock-
down or OSMI-1 treatment (Figures 4G and S10), the translation efficacy of proteasome subunit mRNAs and the
stability of proteasome subunits following their translation might be improved by O-GlcNAcylation.10 iScience 23, 101299, July 24, 2020
Figure 6. Proposed Model by Which Enhanced Protein O-GlcNAcylation Mediates the Cytoprotective Response
to Proteasome Impairment
Proposed schematic models by which enhanced protein O-GlcNAcylation mediates the cytoprotective response to
proteasome impairment. Cells upregulate OGT expression to enhance O-GlcNAcylation of cellular proteins upon
proteasome impairment. O-GlcNAcylation enhances biogenesis and degradation of the proteasome and then maintains
proteasome activity and suppresses cell death. This mechanism may play a redundant role in the Nrf1-mediated bounce-




ArticleIdentificationof theO-GlcNAcylation target proteins responsible for enhancedproteasome turnover is critical to
clarify themechanisms involved. To date, Nrf1-mediated upregulation of proteasome gene expression is widely
known to quantitatively compensate for proteasome impairment, whereas the mechanism by which cells main-
tain proteasome quality control is poorly understood. Our data suggest that O-GlcNAcylation plays a role in
turnover of theproteasome, even in the steady state (Figure 5). Therefore, it is logical to speculate thatO-GlcNA-
cylation constitutively contributes to proteasome quality control, and its significance becomes apparent under
conditions involving proteasome defects.
Recent studies showedthatO-GlcNAcylation is important inbothcancerandneurodegeneration (Maetal., 2017).
Enhanced O-GlcNAcylation is thought to prevent protein phosphorylation by competing with target Ser/Th
residues, and thus the administration of Thiamet-G, anOGA inhibitor, is expected to protect against Alzheimer’s
disease progression by suppressing the phosphorylation of tau proteins (Yuzwa et al., 2008). It has also been
shown that increased O-GlcNAcylation by Thiamet-G decelerates neurodegeneration by stabilizing tau
against aggregation,althoughthedetailedmechanismremainsunclear (Yuzwaetal., 2012).Since theproteasome
plays a pivotal role in thedegradation of tau proteins, the effect of Thiamet-Gmight bemediated inpart bymain-
taining proteasome activity though O-GlcNAcylation (Götzl et al., 2016; Opoku-Nsiah and Gestwicki, 2018).
Proteasome inhibitors have succeeded in improving the clinical outcomes of patients with multiple myeloma,
but acquired resistance to proteasome inhibitors eventually emerges (Wallington-Beddoe et al., 2018). Further-
more, the clinical response to proteasome inhibitors in solid tumors remains poor (Manasanch and Orlowski,
2017; Ruschak et al., 2011). UpregulatedOGT andenhancedO-GlcNAcylation have been reported in some solid
tumors, such as breast andpancreatic cancer (Champattanachai et al., 2013; Krzeslak et al., 2012;Ma et al., 2013).
These findings raise the possibility that enhanced O-GlcNAcylation confers resistance to proteasome inhibitors
in solid cancer cells. Our results in cells and mice reveal that O-GlcNAcylation, in combination with proteasome
inhibitors, is a promising target for cancer treatment.
In conclusion, we identified enhanced O-GlcNAcylation as a regulator of proteasome function under pro-




Articleproteasome activity, as this will provide insight into the design of drugs against cancer and possibly
neurodegeneration.
Limitations of the Study
In the present study, we demonstrated that enhanced O-GlcNAcylation suppressed cell death upon pro-
teasome impairment bymaintaining proteasome activity. However, the distinct targets of O-GlcNAcylation
and the precise mechanisms of O-GlcNAcylation-mediated biogenesis and degradation of the protea-
some remain to be addressed in future studies. Mass spectrometry analysis to identify O-GlcNAcylated
proteins by developing a new method for their purification will provide clues regarding the mechanistic
role of O-GlcNAcylation. We also demonstrated that the proteasome was constitutively degraded by auto-
phagy in mammalian cells. However, the mechanistic interaction between proteaphagy and O-GlcNAcyla-
tion remains unclear. Further investigations are required to characterize the detailed mechanism whereby
O-GlcNAcylation achieves proteasome quality control.
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Lü, S., Yang, J., Song, X., Gong, S., Zhou, H., Guo,
L., Song, N., Bao, X., Chen, P., and Wang, J.
(2008). Point mutation of the proteasome beta5
subunit gene is an important mechanism of
bortezomib resistance in bortezomib-selected
variants of Jurkat T cell lymphoblastic lymphoma/
leukemia line. J. Pharmacol. Exp. Ther. 326,
423–431.
Ma, X., Li, H., He, Y., and Hao, J. (2017). The
emerging link between O-GlcNAcylation and
neurological disorders. Cell. Mol. Life Sci. 74,
3667–3686.
Ma, Z., Vocadlo, D.J., and Vosseller, K. (2013).
Hyper-O-GlcNAcylation is anti-apoptotic and
maintains constitutive NF-kB activity in pancreatic
cancer cells. J. Biol. Chem. 288, 15121–15130.
Maiso, P., Huynh, D., Moschetta, M., Sacco, A.,
Aljawai, Y., Mishima, Y., Asara, J.M., Roccaro,
A.M., Kimmelman, A.C., andGhobrial, I.M. (2015).
Metabolic Signature identifies novel targets for
drug resistance in multiple myeloma. Cancer Res.
75, 2071–2082.
Manasanch, E.E., and Orlowski, R.Z. (2017).
Proteasome inhibitors in cancer therapy. Nat.
Rev. Clin. Oncol. 14, 417–433.
Marshall, R.S., and Vierstra, R.D. (2019). Dynamic
regulation of the 26S proteasome: from synthesis
to degradation. Front. Mol. Biosci. 6, 40.
Moreau, P., Pylypenko, H., Grosicki, S.,
Karamanesht, I., Leleu, X., Grishunina, M.,
Rekhtman, G., Masliak, Z., Robak, T., Shubina, A.,et al. (2011). Subcutaneous versus intravenous
administration of bortezomib in patients with
relapsedmultiple myeloma: a randomised, phase
3, non-inferiority study. Lancet Oncol. 12,
431–440.
Murata, S., Yashiroda, H., and Tanaka, K. (2009).
Molecular mechanisms of proteasome assembly.
Nat. Rev. Mol. Cell Biol. 10, 104–115.
O’Connor, R., Ooi, M.G., Meiller, J., Jakubikova,
J., Klippel, S., Delmore, J., Richardson, P.,
Anderson, K., Clynes, M., Mitsiades, C.S., et al.
(2013). The interaction of bortezomib with
multidrug transporters: implications for
therapeutic applications in advanced multiple
myeloma and other neoplasias. Cancer
Chemother. Pharmacol. 71, 1357–1368.
Oerlemans, R., Franke, N.E., Assaraf, Y.G., Cloos,
J., Van Zantwijk, I., Berkers, C.R., Scheffer, G.L.,
Debipersad, K., Vojtekova, K., Lemos, C., et al.
(2008). Molecular basis of bortezomib resistance:
proteasome subunit25 (PSMB5) gene mutation
and overexpression of PSMB5 protein. Blood 112,
2489–2499.
Opoku-Nsiah, K.A., and Gestwicki, J.E. (2018).
Aim for the core: suitability of the ubiquitin-
independent 20S proteasome as a drug target in
neurodegeneration. Transl. Res. 198, 48–57.
Radhakrishnan, S.K., Lee, C.S., Young, P., Beskow,
A., Chan, J.Y., and Deshaies, R.J. (2010).
Transcription factor Nrf1 mediates the
proteasome recovery pathway after proteasome
inhibition in mammalian cells. Mol. Cell 38, 17–28.
Riz, I., Hawley, T.S., Marsal, J.W., and Hawley,
R.G. (2016). Noncanonical SQSTM1/p62-Nrf2
pathway activation mediates proteasome
inhibitor resistance in multiple myeloma cells via
redox, metabolic and translational
reprogramming. Oncotarget 7, 66360–66385.
Ruschak, A.M., Slassi, M., Kay, L.E., and
Schimmer, A.D. (2011). Novel proteasome
inhibitors to overcome bortezomib resistance.
J. Natl. Cancer Inst. 103, 1007–1017.
Schwartz, A.L., and Ciechanover, A. (2009).
Targeting proteins for destruction by the
ubiquitin system: implications for human
pathobiology. Annu. Rev. Pharmacol. Toxicol. 49,
73–96.
Sekine, H., Okazaki, K., Kato, K., Alam, M.M.,
Shima, H., Katsuoka, F., Tsujita, T., Suzuki, N.,
Kobayashi, A., Igarashi, K., et al. (2018). O
-GlcNAcylation signal mediates proteasome
inhibitor resistance in cancer cells by stabilizing
NRF1. Mol. Cell. Biol. 38, e00252–18.
Steffen, J., Seeger, M., Koch, A., and Krüger, E.
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Figure S1. Knockdown efficiency of Nrf1 and Ump1 and mRNA levels of hexokinase in U2OS cells, related 
to Figure 1.
(A) Relative mRNA expression of Nrf1 and Ump1 in U2OS cells transfected with target siRNAs (siNrf1 or siUmp1) 
or control siRNA for 48h. mRNA levels of target genes were normalized to GUSB mRNA levels. Data are presented 
as the mean ± SEM (n=3). (B) Relative mRNA expression of hexokinase isoforms in U2OS cells. Expression data 
were derived from RNA-seq data. Data in (A) were analyzed by two-tailed Student’s t-test (***p<0.001).




























































Figure S2. No synergistic effect of 2-DG and bortezomib in HK1- knockdown cells, related to Figure 2.
Viability assay of U2OS cells transfected with HK1 siRNA with or without 3 mM 2-DG in the presence of 10 nM BTZ for 
48 h. Data are presented as the mean ± SEM (n=3). The percentage of dead cells was assessed by FACS after 
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Figure S3. Glycolysis does not play an important role in the regulation of cell death upon proteasome 
inhibition, related to Figure 3.
(A) Schematic of the glycolysis pathway. (B) Viability assay of U2OS cells transfected with target siRNAs and then 
treated with 10 nM BTZ for 48 h. (C and D) Viability assay of U2OS cells treated with 10 nM BTZ with or without 25 
mM DCA (C) or 40 mM oxamate (D) for 48 h. (E) Measurement of intracellular ATP levels in U2OS cells treated with 
10 nM BTZ and 25 mM 2-DG for 12 h using the GloMAX Discover System. (F) Relative mRNA expression of HK1 or 
OGT. mRNA levels of target genes were normalized to GUSB mRNA levels. (G) Immunoblot analysis of lysates from 
U2OS cells with antibodies against the indicated proteins. U2OS cells were transfected with HK1 siRNA and then 
treated with 10 nM BTZ and 20 mM GlcNAc for 48 h. The percentage of dead cells was assessed by FACS after 
staining with Hoechst 33342 and PI in (B–D). Data in (B–F) are presented as the mean ± SEM (n=3). Data in (B–E) 
were analyzed by two-way ANOVA followed by Tukey’s test (*p<0.05, n.s.: not significant). Data in (F) were analyzed 
by two-tailed Student’s t-test (*p<0.05, ***p<0.001). 
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Figure S4. Combined treatment with BTZ and OSMI-1 shows synergistic cytotoxicity in U2OS and RPMI8226 
cells, related to Figure 3.
(A) Viability assay of U2OS cells treated with 10 nM BTZ and 1 mM 2-DG with or without 20 mM GlcNAc for 48 h. (B) 
Viability assay of B16 cells treated with various concentrations of CFZ and OSMI-1 for 48 h. Data are presented as 
the mean (n=3). (C) Viability assay of U2OS cells transfected with OGT siRNAs (siOGT#01 and siOGT#02) or control 
siRNA, and then treated with various concentrations of CFZ for 48 h. (D and E) Viability assay of U2OS and 
RPMI8226 cells treated with various concentrations of BTZ and OSMI-1 for 48 h. Data are presented as the mean 
(n=3). The percentage of dead cells was assessed by FACS after staining with Hoechst 33342 and PI in (A-E). Data 
in (A and C) are presented as the mean ± SEM (n=3). Data in (A) were analyzed by two-tailed Student’s t-test 
(**p<0.01).
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Figure S5. Combined treatment with OSMI-1 and small molecule inhibitors other than proteasome inhibitors 
does not show synergistic cytotoxicity in B16 cells, related to Figure 3.
(A) Viability assay of B16 cells treated with various concentrations of OSMI-1 and thapsigargin for 48 h. (B) Viability 
assay of B16 cells treated with various concentrations of OSMI-1 and nocodazole for 48 h. (C) Viability assay of B16 
cells treated with various concentrations of OSMI-1 and cisplatin for 48 h. (D) Viability assay of B16 cells treated with 
various concentrations of OSMI-1 and 5-FU for 48 h. The percentage of dead cells was assessed by FACS after 










Bliss sum: 14.7 Bliss sum: -50.1
Bliss sum: -114.9 Bliss sum: -94.2






















































































0 5 10 20 400 5 10 20 400 5 10 20 400 5 10 20 40

































































PI positive cells /%































Figure S6. Inhibition of O-GlcNAcylation sensitizes BTZ-resistant cells to the cytotoxic effect of BTZ in an
Nrf1-independent manner, related to Figure 4. 
(A and B) Viability assay of parental U2OS and U2OS/BTZ cells (A) or parental B16 and B16/BTZ cells (B) treated 
with 100 nM BTZ for 48 h. (C and D) Viability assay of U2OS/BTZ and B16/BTZ cells treated with various 
concentrations of BTZ and OSMI-1 for 48 h. Data are presented as the mean (n=3). (E) Relative mRNA expression 
of Nrf1 in Nrf1-knockout HCT116 cells. mRNA levels of target genes were normalized to GUSB mRNA levels. (F) 
Immunoblot analysis of lysates from Nrf1-knockout HCT116 cells with antibodies against the indicated proteins. 
Nrf1-knockout HCT116 cells were treated with 10 nM BTZ for 48 h. (G) Relative mRNA expression of Nrf1 in Nrf1-
knockout HCT116 cells treated with or without 10 nM BTZ for 12 h. mRNA levels of target genes were normalized 
to GUSB mRNA levels. The percentage of dead cells was assessed by FACS after staining with Hoechst 33342 
and PI (A–D). Data in (A, B, and E) are presented as the mean ± SEM (n=3). Data in (A) and (B) were analyzed by 
two-way ANOVA followed by Tukey’s test (***p<0.001). Data in (E) were analyzed by Tukey’s test (***p<0.001). 
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Figure S7. Increased protein O-GlcNAcylation suppressed cell death under proteasome impairment in HeLa 
cells, related to Figure 5
(A) Viability assay of HeLa cells treated with various concentrations of BTZ and 2-DG for 48h. (B) Relative mRNA 
expression of HK1 and OGT in HeLa cells. mRNA levels of target genes were normalized to GUSB mRNA levels. (C) 
Immunoblot analysis of lysates from HeLa cells with antibodies against the indicated proteins. HeLa cells were treated 
with 10nM BTZ for 48h. (D) Viability assay of HeLa cells treated with various concentration of BTZ and OSMI-I for 48h. 
Data are presented as the mean (n=3). (E) Immunoblot analysis of lysates from HeLa cells with antibodies against the 
indicated proteins. HeLa cells were treated with 10 nM BTZ for 48h and with 20 μΜ OSMI-I for 24h. (F) Proteasome 
peptidase activity of lysates from HeLa cells treated with 10 nM BTZ for 48h and 20μM OSMI-I for 24h. (G) HeLa Rpn11-
Halo knock-in cells were transfected with OGT siRNAs (siOGT#01 and siOGT#02) or control siRNA and then treated 
with 200 nM BTZ . After 4h, BTZ was washed out and were stained with TMR ligand and subsequently subjected to the 
blocking ligand. Cells were incubated at 37℃ for the indicated times. The percentage of dead cells was assessed by 
FACS after staining with Hoechst 33342 and PI (A and D). Data in (B, F, and G) are presented as the mean ± SEM 
(n=3). Data in (B) were analyzed by two-tailed Student’s t-test (***p<0.001). Data in (F and G) were analyzed by Tukey’s 
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Figure S8. O-GlcNAcylation enhances turnover of the proteasome in U2OS and B16 cells, related to Figure 5.
(A) U2OS Rpn11-Halo knock-in cells were treated with 200 nM BTZ or 20 μM OSMI-I cells. After 4 h, BTZ was washed out and cells 
were stained with TMR ligand and subsequently subjected to the blocking ligand. Cells were incubated at 37℃ for the indicated times. 
(B) U2OS Rpn11-Halo knock-in cells were treated with the blocking ligand. Cells were incubated at 37℃ for 6 h and then stained with 
TMR ligand. (C) U2OS Rpn11-Halo knock-in cells were treated with 30 nM CFZ or 20 μM OSMI-1. After 4 h, CFZ was washed out 
and then, cells were incubated at 37℃ for 18 h. Cells were lysed and immunoprecipitated with HaloLinkTM Resin. (D) Immunoblot 
analysis of lysates from U2OS Rpn11-Halo knock-in cells treated as in (C) with antibodies against the indicated proteins. Relative 
band intensity values for α6 and Rpn8 were normalized to those for β-actin. (E) B16 Rpn11-Halo knock-in cells were treated as in (A). 
(F) B16 Rpn11-Halo knock-in cells were treated as in (B). (G) B16 Rpn11-Halo knock-in cell were treated as in (C). (H) Immunoblot 
analysis of lysates from B16 Rpn11-Halo knock-in cells treated as in (G) with antibodies against the indicated proteins. Relative band 
intensity values for α6 and Rpn8 were normalized to those for β-actin. Data in (A–H) are presented as the mean ± SEM (n=3). Data 
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Figure S9. OGT inhibition does not affect ABCB1 activity, related to Figure 5.
(A) ABCB1 activity assay with U2OS cells transfected with target siRNA (siOGT#01 and siOGT#02) or control 
siRNA, and then stained with rhodamine 123. (B) ABCB1 activity assay with U2OS cells treated with 20 μM OSMI-1 
for 24 h or 10 μM cyclosporine A (CsA) for 12 h, and then stained with rhodamine 123. Data in (A and B) are 





+    - - +    - -
- +     - - +    -
- - +   - - +   
***
***






+ - - + -


















































10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Fraction number
Figure S10. Inhibition of O-GlcNAcylation does not cause defects in proteasome assembly, related to 
Figure 5.
(A) Lysates from U2OS cells were fractionated by glycerol gradient centrifugation (8 to 32% glycerol from fraction 1 
to 30), and an equal volume of each fraction was assayed for proteasome peptidase activity using the substrate 
Suc-LLVY-MCA with or without SDS. U2OS cells were treated with 10 nM BTZ for 48 h, with or without 20 μM
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Table S1. List of the final 28 hits and the scores in the siRNA screen, related to Figure 1.
1st screen 2nd screen































Cell culture and transfection 
U2OS, B16, HCT116, and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM, Nacalai Tesque) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher 
Scientific). RPMI8226 cells were cultured in RPMI 1640 medium (Nacalai Tesque) supplemented 
with 10% FBS. All cell lines were tested for Mycoplasma by DAPI staining. The authors performed 
no further authentication of the cell lines. For plasmid transfection, all cell lines were transfected 
using PEI-MAX (Polysciences). U2OS cells stably expressing the ZsProsensor-1 fusion protein 
(TaKaRa Bio) were selected with puromycin (2 μg mL-1 final concentration). siRNAs targeting HK1 
and OGT and siGENOME Non-Targeting siRNA #2 were purchased from Dharmacon. All cell 
lines were transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen). Cells were 
harvested 72 h after siRNA transfection. 
The siRNA sequences were as follows: 
HK1 siRNA1: 5’-GGAAGGAGAUGAAGAAUGG-3’ 
HK1 siRNA2: 5’-GAAGUUACCUGUGGGAUUC-3’ 
OGT siRNA1: 5’-CGACAUGCAUUGCGUCUCA-3’ 
OGT siRNA2: 5’-GAUUAAGCCUGUUGAAGUC-3’ 
 
siRNA screen 
The Dharmacon siGENOME SMARTpool siRNA library (GE Dharmacon) was dispensed in glass-
bottom, black, 384-well plates (Greiner). The siRNAs were suspended in 1× siRNA buffer (Thermo 
Fisher Scientific), and 2.5 pmol siRNA (2.5 μL/well) was seeded in each well. Lipofectamine 
RNAiMAX (0.1 μL) was added to 10 μL DMEM, and 3.0 × 103 U2OS cells in 40 μL normal media 
were seeded in each well. After 16 h of culture, bortezomib (10 nM final concentration) was added 
to each well. Cells were stained with a mixture of 10 μL DMEM, Hoechst 33342 (Nacalai Tesque, 
0.2 μg ml-1 final concentration), and propidium iodide (PI; Nacalai Tesque, 1.0 μg mL-1 final 
concentration) after 44 h of bortezomib treatment. After 30 min of incubation at 37 °C, media were 
replaced with 20 mM Tris-HCl buffer (pH 8.0) containing 2% w/v DABCO (Nacalai Tesque), and 
fluorescence images were acquired using the CellInsight High Content Screening Platform 
(Thermo Fisher Scientific). The percentage of PI-positive cells was fitted using a two-way median 
polish method to exclude positional effects in the plates, and the B score was calculated by using 
the following formula. 
B score = (XsiRNA - MediansiRNA) / MAD 
(XsiRNA: measured percentage of PI-positive cells, MAD: median of absolute deviation). 
For the secondary screen, assay plates containing four individual siRNAs purchased from 
Dharmacon were prepared and analyzed by the same method as for the primary screen. 
 
Cell viability assay using flow cytometry 
Cells treated with drugs or siRNAs were resuspended in DMEM containing Hoechst 33342 (1.0 
μg ml-1 final concentration) and PI (1.0 μg ml-1 final concentration). After 15-min incubation at 
room temperature, the cells were immediately analyzed by Attune NxT (Thermo Fisher Scientific). 
 
Establishment of bortezomib-resistant cell lines 
Two bortezomib-resistant cell lines, U2OS/BTZ and B16/BTZ, were generated from their parental 
cell lines by continuous exposure to bortezomib. The concentration of bortezomib was increased 
stepwise (10-50 nM) for 3 months. 
 
Generation of knockout cells 
Knockout cell lines were generated using the CRISPR/Cas9 system. The single-guide RNA 
(sgRNA) sequence was cloned into the pX330 vector (Addgene). The sgRNA sequence for Nrf1 
was 5’-TCCGTTAAGTATTTCTTCAG-3’. To generate Nrf1-knockout cells, a targeting vector and 
sgRNA vector were transfected into HCT116 cells, and the cells were selected with puromycin. 




Total RNA was extracted from U2OS cells using a High Pure RNA isolation kit (Roche). RNA-seq 
libraries were obtained using the TruSeq library preparation kit. U2OS cells were treated with 
bortezomib (10 nM final concentration) for 30, 60, and 120 h. Culture medium containing 
bortezomib was replaced every 12 h. RNA-seq libraries were sequenced for 91 cycles using a 
HiSeq 4000 sequencer (Illumina) to obtain paired-end reads. Sequence reads were mapped to 
the human genome (hg19) and processed by TopHat and Cufflinks. Gene ontology (GO) analyses 
were performed using DAVID version 6.8. RNA-seq data were deposited in the DDBJ Sequenced 
Read Archive under the accession number DRA008318. Processed data files have been 
submitted to the Genomic Expression Archive under the accession number ESUB000511.  
 
Quantitative RT-PCR 
For quantitative RT-PCR analysis, total RNA was isolated from cells using a High Pure RNA 
isolation kit (Roche) and reverse transcribed with a ReverTra Ace qPCR RT kit (Toyobo). 
Quantitative RT-PCR was performed using THUNDERBIRD Probe qPCR Mix (Toyobo) and 
Universal ProbeLibrary Probe (Roche) on a LightCycler 480 (Roche). 
The quantitative RT-PCR primer sequences were as follows: 
GUSB: forward: 5’-CGCCCTGCCTATCTGTATTC-3’ 
reverse: 5’-TCCCCACAGGGAGTGTGTAG-3’ 
PSMB7: forward: 5’-CAGCAATGGCTGTATTTGAAGA-3’ 
reverse: 5’-GGCTTCGCTCACCAGATTC-3’ 
Nrf1: forward: 5’-AGTGGAGACTTAACCAAAGAGGAC -3’ 
reverse: 5’-CTCCTTCTGGCGGTGACTAT-3’ 




Cells were lysed in lysis buffer (25 mM Tris-HCl [pH 7.5], 0.2% [v/v] NP-40, 5 mM MgCl2, 1 mM 
dithiothreitol (DTT), and 2 mM ATP), and the extracts were centrifuged at 20,000 ×g for 30 min at 
4 °C. The supernatants were separated by SDS-PAGE and glycerol gradient centrifugation. The 
method for 8 to 32% (v/v) linear glycerol gradient centrifugation (22 h, 83,000 ×g) was described 
previously (Hamazaki et al., 2015). For immunoprecipitation, cells were lysed in 
immunoprecipitation lysis buffer (0.5% [v/v] NP-40, PBS) and immunoprecipitated with beads 
tagged with anti-DYKDDDDK (Wako), or lysed in lysis buffer (25 mM Tris-HCl [pH 7.5], 0.2% [v/v] 
NP-40, 5 mM MgCl2, 1 mM DTT, and 2 mM ATP) and immunoprecipitated with anti-Rpt6 antibody 
as described previously (Hamazaki et al., 2015). The samples were resolved by SDS-PAGE and 
transferred to polyvinylidene fluoride membranes. All images were acquired using a Fusion SL4 
system (M&S Instruments). The antibodies for α3, α6, β2, Rpt4, Rpt6, and Rpn8 were described 
previously (Hirano et al., 2005; Kaneko et al., 2009). Antibodies against the following proteins or 
molecules were purchased: OGT (ab96718; Abcam), β-actin (MAB1501; Millipore), O-GlcNAc 
(ab2739; Abcam), ubiquitin (AB120; LifeSensors), and Nrf1 (c-19; Santa Cruz). Quantification of 
bands was performed using ImageJ. 
 
Proteasome activity assay 
Cells were lysed in lysis buffer (25 mM Tris-HCl [pH 7.5], 0.2% [v/v] NP-40, 5 mM MgCl2, 1 mM 
DTT, and 2 mM ATP). Samples were mixed with the proteasome substrate succinyl-Leu-Leu-Val-
Tyr-7-amino-4-methylcoumarin (Suc-LLVY-MCA) (Peptide Institute) and incubated at 37 °C. 
Proteasome peptidase activity was measured by an ARVO MX 1420 (PerkinElmer). U2OS and 
HEK293T cells stably expressing ZsGreen-mODC were treated with drugs, resuspended in 
DMEM, and analyzed by an Attune NxT. 
 
HaloTag assay 
For HaloTag labeling, HeLa Rpn11-Halo knock-in cells were cultured in medium containing 10 
nM tetramethylrhodamine (TMR; Promega) or 10 μM of the blocking reagent succinimidyl ester 
(O4; Promega) for 15 min and washed twice with PBS. O4 was incubated with 100 mM Tris-HCl 
(pH 8.0) for 60 min at 25 °C before use. Cells were analyzed by Attune NxT. For 
immunoprecipitation, cells were lysed in lysis buffer (25 mM Tris-HCl [pH 7.5], 0.2% [v/v] NP-40, 
5 mM MgCl2, 1 mM DTT, and 2 mM ATP), and the extracts were centrifuged at 20,000×g for 30 
min at 4 °C. The supernatants were immunoprecipitated with HaloLinkTM Resin (Promega) for 16 
h at 4 °C.  
 
Intracellular ATP assay 
Cells in 384-well plates were treated with 25 μL Cell ATP Assay Reagent (TOYO B-Net). Cells 
were incubated at 23 °C for 10 min and then measured using a GloMAX Discover System 
(Promega). 
 
ABCB1 activity assay 
Cells were treated with 1.0 μg/mL rhodamine 123 at 37 °C for 30 min. After incubation, cells were 
washed once with DMEM and then resuspended in DMEM. For washout samples, cells were 
incubated with rhodamine 123-free DMEM for 45 min before being resuspended in DMEM. Cells 
were immediately analyzed by an Attune NxT (Thermo Fisher Scientific). 
 
Protein biotinylation and purification 
Cells were treated with 50 μM GlcNAz (Click-iT GlcNAz; Thermo Fisher Scientific). Cell lysis and 
click chemistry-based reactions were performed using a Click-iT protein reaction buffer kit and 
biotin-alkyne (Thermo Fisher Scientific). Biotinylated proteins were immunoprecipitated using 
Dynabeads MyOne Streptavidin C1 (Invitrogen) following the manufacturer’s protocols. 
 
Animal studies 
All animal experimental protocols were approved by the Institutional Animal Care Committee of 
the Graduate School of Pharmaceutical Sciences, the University of Tokyo (approval number M25-
19). C57BL/6N mice aged 5-7 weeks (CLEA Japan, Inc.) were inoculated subcutaneously in their 
right flank with 3.0 × 106 B16 cells suspended in 200 μL of a 1:1 mixture of DMEM and Matrigel 
(Corning). Mice were intraperitoneally injected with 2-DG (Wako Pure Chemical Industries, 1500 
mg kg-1) and bortezomib (LC Laboratories, 0.5 mg kg-1) or intravenously injected with bortezomib 
(0.5 mg kg-1) and OSMI-1 (Cayman Chemical Company, 0.5 mg kg-1) three times per week. 
Concentrations of 2-DG and bortezomib were determined according to previous studies (Amodio 
et al., 2019; Maschek et al., 2004). Regarding OSMI-1, several concentrations were tested to 
determine that at which a single dose of OSMI-1 did not cause any harmful effects in mice. Mice 
in the control group received vehicle. Tumor length (a) and width (b) were measured using a 
digital caliper, and tumor volume (V) was calculated using the following equation: V=a×b2 / 2. After 
14 days of treatment, the mice were euthanized and the tumors were analyzed. 
 
Statistical analysis 
Quantitative data are presented as the mean ± standard error of mean (SEM) derived from three 
independent experiments, unless otherwise noted. Drug synergy was evaluated using the Bliss 
independence model (BLISS, 1939). Drug synergy represented by the Bliss score was calculated 
by subtracting the percent expected PI-positive cells from the percent observed PI-positive cells 
for each combination of drug doses. The Bliss expectation was calculated with the equation (A + 
B) – A × B, where A and B are the fraction of PI-positive cells induced by the combination of agents 
A and B at a given dose. The Bliss sum is the sum of all Bliss scores in a given matrix. Bliss sums 
greater than zero, close to zero, and less than zero denote synergy, additionally, and antagonism, 
respectively. In general, animal experiments with tumor allografts were performed with five mice 
per group. No statistical methods were used to predetermine sample size. The investigators were 
not blinded to allocation during the experiments or the outcome assessments. Statistical analysis 
of quantitative data was performed using two-tailed Student’s t-test or Tukey’s test followed by 
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